Image via

Using cannabis to unwind after work does not reduce workplace performance, according to a new study published in the Group & Organization Management journal. 

Researchers from San Diego State and Auburn University conducted the study to shed some light on the current stigma against using pot in the workplace. The researchers note that although millions of Americans are currently using cannabis today, either medicinally or recreationally, most of the research on the topic was conducted in the ’70s and ’80s.

“Although it is common for organizations to screen employees and applicants for substances including cannabis and for politicians and societal leaders to make sweeping claims about cannabis, there is virtually no empirical research exploring cannabis use in relation to the modern workplace,” the authors explain. “Dated research that offers limited empirical evidence is a serious concern for organizations, governments, and society.” 

The study authors interviewed 281 employees and their supervisors about cannabis use and its potential impact on workplace performance. The researchers asked each employee to report how often they used pot during their average workday, including two hours before and two hours after work. Supervisors were then asked to evaluate each employee on three categories: Task performance, or how well each employee did their job; citizenship behavior, or willingness to help other employees; and counterproductive work behavior. 

Researchers then compared each employee’s evaluations with their self-reported pot use to look for connections. The analysis showed that employees who got high before or during work were more likely to receive lower ratings for task performance and counterproductive work behaviors from their supervisors. Getting high before or during work also had a negative impact on citizenship behaviors focused towards the organization, but not on citizenship behaviors towards other employees.

Workers who used cannabis after work did not show any signs of reduced workplace performance, counterproductive work behavior, or negative social behavior. “After-work cannabis use did not relate to any of the workplace performance dimensions,” the authors wrote. “This finding casts doubt on some stereotypes of cannabis users and suggests a need for further methodological and theoretical development in the field of substance use.”

The findings raise concerns about the problematic use of workplace drug testing for cannabis. Because the body takes a long time to metabolize THC and other cannabinoids, a standard urinalysis test is unable to pinpoint the exact time that a person used cannabis. A person who hit a joint at a party one weekend and abstained during the work week is just as likely to fail a piss test as someone who smokes all day every day. 

Although this study makes it clear that using pot at work can impact performance, it also shows that after-hours use does not interfere with employees’ ability to do a good job. But, due to the inefficiency of urine tests, an employee is just as likely to be fired for safe after-work use as they are for getting stoned at work. The researchers hope that their current study will be a springboard for future research into cannabis and the modern workplace.

“To our knowledge, this is the first study using temporal cannabis items in relation to different forms of workplace performance,” the authors explained. “This is also the first study isolating cannabis in relation to workplace behaviors in nearly 20 years.”

There have been a few recent studies that have touched on the topic, though. In 2018, researchers found that workplace fatalities have been significantly declining in states with legal medical marijuana. And another study from the same year found that 63 percent of employees working in Colorado’s legal cannabis industry admitted to being high at work, but did not indicate any negative impact related to on-the-job use.

Read More

Looking for a sweet gig? The Food and Drug Administration (FDA) posted a notice last week in search of somebody to sample and assess thousands of CBD products.

Before you update your resumé, though, let’s be clear: The agency is actually seeking to award a contract to a professional scientific company that will conduct tests and analyze CBD levels in marketplace items. The aim is to gather data that will help shape federal regulations going forward.

It’s a big job. The testing body will be in charge of gathering between 1,000 and 3,000 samples from CBD-infused items that are presently for sale across the United States. For example, the FDA lists “beverages, water, candy, baked goods, oils and tinctures that can be added to human or animal foods, including pills, capsules, gel caps, gummies, and other forms.”

Once rounded up, the contractor will analyze the material for CBD and other cannabinoid components by way of approved methodologies such as liquid and gas chromatography. The contractor will also look for pesticides, residual solvents, microbiological contaminants, and other toxic elements that will harsh your mellow.

“In addition,” the FDA wrote, “this task order will be used to collect cosmetic samples for shipment to a third party for analysis. The purpose of these studies will be to develop a better understanding of the quantities of CBD and associated cannabinoids and their distribution. The goal will be to collect and analyze a statistically relevant number of samples. The reliability of the results will be supported by specified quality assurance/quality control processes within the study.”

The agency also wrote that the final results “will not only be reported to Congress, but will also be used to guide the development of future policy.”

Last month, the FDA submitted an updated report to Congress on its ongoing CBD product inquiries, which concluded that inconsistency and mislabeling are considerable issues in the current marketplace. On the positive side, the FDA said it found no discernible presence of dangerous metals or minerals added to CBD products.

“FDA recognizes the significant public interest in CBD products,” the agency stated. “However, there are many questions about the characteristics of currently marketed CBD products because the Agency lacks significant information on what CBD-containing products are on the market and there is little data available on those products themselves.”

The next step for the FDA was to post its want ad for an outside contractor. If you do fit the bill after all, the due date to submit your application is August 31.

Read More
Call Now
Are you 21 or older? This website requires you to be 21 years of age or older. Please verify your age to view the content, or click "Exit" to leave.
Enable Notifications Yes, please keep me updated No thanks
Skip to toolbar